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Troglitazone is one of the thiazolidinedione (TZD) class of anti-diabetic drugs and a ligand for peroxisome
proliferator-activated receptor c (PPARc). Troglitazone and other PPARc ligands have been shown to inhibit cell
proliferation and induce cell cycle arrest in a variety of cancer cells, and have been considered as potential tumor
preventive and tumor therapeutic agents. Little is known, however, about how normal or initiated cells respond to
these agents during mouse skin carcinogenesis. We report here that troglitazone and another TZD, ciglitazone,
dramatically inhibited mitogen-induced cellular proliferation in normal mouse skin primary keratinocytes and in the
C50 keratinocyte cell line. This was accompanied by induction of cell cycle G1 phase arrest and suppression of
cyclin D1, cdk4, and cdk2 expression. Troglitazone suppressed cyclin D1 expression at multiple levels. In addition,
we demonstrated that PPARc was not expressed at functional levels in cultured mouse skin keratinocytes, and that
the inhibitory effects of troglitazone on cellular proliferation and cyclin D1 expression in these cells were PPARc-
independent. Given the important role of keratinocyte proliferation in skin carcinogenesis, our data suggest that
TZD may be useful tumor preventive agents in skin.
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Peroxisome proliferator-activated receptors (PPAR) are
ligand-activated transcription factors that belong to the
nuclear receptor superfamily (Issemann and Green, 1990).
Three isoforms, namely, PPARa, PPARd, and PPARg, have
been identified so far and PPARg is one of the most
intensively studied PPAR isoforms. Ligand-activated PPARg
transactivates genes by heterodimerizing with retinoid X
receptor and binding to a consensus DNA sequence called
PPAR response element (PPRE) in the promoter region of
target genes. PPARg plays a key role in adipogenesis (Barak
et al, 1999). PPARg knockout mice are embryonic lethal and
are completely devoid of all types of adipose tissue (Barak
et al, 1999). Consistent with a role of PPARg in lipid
metabolism, several metabolites of arachidonic acid have
been found to be selective PPARg ligands with high affinity.
These include 15-deoxy-D12,14-prostaglandin J2 (15-
PGJ2), 13-hydroxyoctadecadienoic acid and 15-hydroxy-
eicosatetraenoic acid (reviewed in Rosen and Spiegelman,
2001). Interestingly, thiazolidinediones (TZD), a novel class
of synthetic anti-diabetic drugs, were also identified as
selective PPARg ligands (Lehmann et al, 1995).
Studies using PPARg ligands have implicated PPARg in
many diverse pathways including control of cellular pro-
liferation and differentiation. For instance, ligand activation
of endogenous or ectopically expressed PPARg is sufficient
to induce growth arrest in fibroblasts and preadipocytes
and leads to formation of adipocytes (Altiok et al, 1997). The
growth arrest is due to a decrease in DNA binding and
transcriptional activity of the E2F/DP complex. This ob-
servation has led to successful efforts in using PPARg
ligands to induce growth arrest and terminal differentiation
in cultured human liposarcoma cells (Tontonoz et al, 1997).
PPARg ligands were later found to have the capacity to
inhibit cell growth in a wide variety of tumor cells not
necessarily of adipose lineage (reviewed in Fajas et al,
2001). Notably, application of troglitazone, a TZD drug,
leads to cell growth arrest and induces expression of
differentiation markers in a number of colon cancer cell lines
(Sarraf et al, 1998). Tumors derived from human colon
cancer cells grown in nude mice were 50% smaller when
mice were fed troglitazone (Sarraf et al, 1998). Similarly,
troglitazone inhibits clonal growth of MCF-7 breast cancer
cells. The retinoic acid receptor ligand all-trans-retinoic acid
synergizes the inhibitory effect of troglitazone and irrever-
sibly leads to apoptosis of MCF-7 cells (Elstner et al, 1998).
Normal human prostate expresses very low levels of PPARg
and PPARg levels are highly elevated in prostate tumors.
Culture of surgically obtained human prostate cancer
tumors with troglitazone produces marked and selective
necrosis of the cancer cells (about 60%) but not the
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adjacent normal prostate cells (Kubota et al, 1998). These
findings have raised considerable interest in the possible
use of PPARg ligands as tumor-preventive and tumor-
therapeutic agents.
Although most studies focus on the anti-growth effect of
PPARg ligands on tumor cells, very little is known about how
normal cells respond to these ligands during carcinogen-
esis. We show here that TZD dramatically inhibited mitogen-
induced cellular proliferation and caused a G1 phase arrest
in normal mouse skin keratinocytes. The cell cycle arrest by
troglitazone was accompanied by suppression of cyclin D1
expression at multiple levels. Unexpectedly, we found that
PPARg was not expressed at functional levels in cultured
keratinocytes. Our data indicate that troglitazone inhibits
cyclin D1 expression and mouse skin keratinocyte prolif-
eration through PPARg-independent mechanisms.
Results
Inhibition of cellular proliferation and cell cycle pro-
gression of keratinocytes by troglitazone To test
whether TZD have the potential to be used as tumor-
preventive agents in mouse skin, we determined whether
TZD could affect the proliferative response of normal
keratinocytes to mitogen stimulus. We cultured primary
keratinocytes and C50 cells in serum-free medium (KGM-2
(keratinocyte growth medium-2)) for 2 d without changing
medium. Cells were then stimulated with fresh KGM-2
medium and treated with the PPARg ligand troglitazone.
KGM-2 medium contains epidermal growth factor and
insulin and other components that are required for growth
of keratinocytes. [3H]thymidine incorporation assay reflects
cellular DNA synthesis activity and is frequently used as
a marker of cellular proliferation. As shown in Fig 1a,
application of fresh KGM-2 medium stimulated DNA
synthesis activity in primary keratinocytes at 12 and 24 h
and troglitazone suppressed this induction in a dose-
dependent manner. Five mM troglitazone inhibited DNA
synthesis by 97.2% (po0.01) at 24 h. The increased DNA
synthesis activity at 12 and 24 h in the control cells is likely
the result of quiescent cells re-entering the cell cycle after
stimulation by fresh medium. DNA synthesis in the control
cells was almost unchanged at 6 h compared with 3 h,
suggesting that it took more than 6 h for these quiescent
cells to re-enter the cell cycle and finally reach S phase. The
inhibitory effect of troglitazone on DNA synthesis, however,
was already evident as early as 3 h. We interpret this to
mean that troglitazone inhibits keratinocyte proliferation by
inhibiting the progression of cycling cells into S phase at
least at early time points. We do not know from these data
whether troglitazone also inhibits the re-entry of quiescent
cells into cell cycle. Troglitazone inhibited DNA synthesis of
C50 cells in a similar pattern (data not shown and Fig 1b).
Another TZD compound ciglitazone also inhibited C50
cell proliferation in a concentartion-dependent manner, al-
though it is not as potent as troglitazone (Fig 1b).
To gain insight as to what phases of the cell cycle are
affected by troglitazone, C50 cells were treated with 1 or 5
mM troglitazone for 24 h and flow cytometry for DNA con-
tent analysis was performed. Although 1 mM troglitazone
showed no effect on cell cycle of C50 cells, 5 mM
troglitazone induced a strong accumulation of cells in G1
phase (Fig 2b and c). These data provide evidence that
troglitazone inhibits the transition of cells from G1 phase to
S phase. Five mM ciglitazone induced a similar G1 phase
arrest. Interestingly, it also slightly increased G2 phase
population in C50 cells (Fig 2d).
Suppression of cyclin D1 expression by troglitazone To
investigate the mechanisms responsible for the G1 arrest
by troglitazone, we examined its effect on the expression
of cell cycle proteins by western blot analysis. Change of
medium at the beginning of treatment caused increased
protein expression of cyclin D1, cdk2, and cdk4 in the
control group. Cyclin D1 and cdk2/cdk4 protein levels,
however, remained low for up to 24 h when C50 cells were
Figure1
Inhibitory effect of thiazolidinediones (TZD) on DNA synthesis
of keratinocytes. (a) Mouse skin primary keratinocytes at 80%
confluence were stimulated with fresh keratinocyte growth medium-2
(KGM-2) medium and treated with vehicle (control) or 1–5 mM
troglitazone (Trog 1–5) for the indicated periods of time. (b) C50 cells
at 80% confluence were not stimulated or stimulated with fresh KGM-2
medium and treated for 24 h with vehicle, 5 mM Trog (Trog 5), 1 or 5 mM
ciglitazone (cig 1 or cig 5, respectively). Cells were pulsed with 1 mCi
per mL of [3H]thymidine for 2 h before harvest. The [3H]thymidine
([3H]TdR) incorporated by cells was measured and normalized to pro-
tein concentration. Cells were treated in triplicate. A set of represent-
ative data from three independent experiments is presented and values
are presented as mean  SD. po0.01; po0.05 versus vehicle
control of similar conditions; # po0.05 versus vehicle control at 3
or 6 h.
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treated with 5 mM troglitazone (Fig 3a). We did not see
significant changes in other cyclins or the cdk inhibitor p21
up to 24 h after troglitazone treatment (Fig 3a). Troglitazone
inhibited expression of cyclin D1, cdk2/cdk4 in a similar
pattern in primary keratinocytes as in C50 cells (Fig 3b).
Inhibition of cyclin D1 was evident as early as 2 h (Fig 3b),
although changes in cdk2/cdk4 levels only occurred after
6 h. These findings suggest that cyclin D1 may be an
important target for troglitazone in terms of cell cycle arrest,
especially with respect to the G1 phase arrest.
Next, we were interested in determining how cyclin D1
was regulated by troglitazone. As shown in Fig 4a, 5 mM
troglitazone suppressed mitogen-induced cyclin D1 mRNA
expression in C50 cells, suggesting that troglitazone may
inhibit cyclin D1 expression at the transcriptional level. We
tried to determine the effect of troglitazone on cyclin D1
mRNA stability using actinomycin D, but we were not
successful because actinomycin D appeared to stabilize
existing cyclin D1 mRNA (data not shown), as has been
reported by others (Lin et al, 2000). To further show that
troglitazone inhibits cyclin D1 expression at the transcrip-
tional level, primary keratinocytes were transiently trans-
fected with a luciferase reporter construct under the control
of a 1745 bp cyclin D1 promoter. Treatment of various
concentrations of troglitazone inhibited cyclin D1 promoter
activity in a concentration-dependent manner (Fig 4b).
Similar results were obtained in C50 cells (data not shown).
Since the inhibitory effect of troglitazone on cyclin D1
expression at the protein level appears stronger than at the
mRNA level, we suspected that regulation other than at the
level of transcription may also be involved. Cyclin D1 protein
degradation is a possible target for regulation by troglita-
zone (Qin et al, 2003). We blocked proteasome activity by
using proteasome inhibitors prior to troglitazone treatment
and found that the proteasome inhibitors Alln and MG-132
partially inhibited the effect of troglitazone on cyclin D1
protein expression in C50 cells (Fig 5a and b). Troglitazone
alone reduced cyclin D1 protein levels by 53%–55% of
control levels, but only by 15%–18% of control levels in the
presence of Alln or 10 mM MG-132 (Fig 5a and b). We further
examined the effect of troglitazone on the ubiquitination of
cyclin D1 protein by immunoprecipitation. Troglitazone
increased cyclin D1-bound ubiquitin, a small polypeptide
that targets proteins for degradation through proteasomes
(Fig 5c). These results suggest that troglitazone reduces
cyclin D1 expression at least partially by enhancing degra-
dation of cyclin D1 protein through the proteasome pathway.
It has been shown that TZD drugs inhibit translation
initiation in mouse embryonic stem cells (Palakurthi et al,
2001). To explore this possibility in keratinocytes, we
measured the effect of troglitazone on incorporation of
[35S]methionine in C50 cells. As shown in Fig 6a, 5 mM
troglitazone inhibited total protein synthesis by 26% at 6 h.
This may partially account for the inhibitory effect of
troglitazone on cell proliferation and cyclin D1 expression
Figure 2
Cell cycle arrest induced by troglitazone (Trog). C50 cells at 80%
confluence were stimulated with fresh keratinocyte growth medium-2
(KGM-2) medium and treated for 24 h with (a) vehicle, (b) 1 mM Trog
(Trog), (c) 5 mM Trog (Trog), (d) 5 mM ciglitazone (cig). Propidium iodide-
stained single-cell suspensions were obtained and DNA content
analyses were performed. A set of representative data from two
independent experiments is presented.
Figure3
Suppression of mitogen-induced cell cycle protein expression by
troglitazone (Trog). C50 cells (a) or primary keratinocytes (b) were
stimulated with fresh keratinocyte growth medium-2 (KGM-2) medium
and treated with 5 mM Trog (Trog) for the indicated periods of time.
Attached cells were harvested in radioimmunoprotein assay buffer.
Thirty micrograms protein from whole-cell extracts was used for
western blot analysis and immunostained with antibodies against
indicated proteins. A set of representative data from at least two
independent experiments is presented.
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shown in Figs 1 and 3. Inhibition of cyclin D1 incorporation
of [35S]methionine by troglitazone, however, was much
stronger (45%) than of total protein incorporation (Fig 6b),
which is consistent with the observation that troglitazone
also inhibits cyclin D1 transcription and enhances cyclin D1
protein degradation.
Lack of involvement of PPARc in troglitazone-induced
growth inhibition It has been clearly demonstrated that
troglitazone and other TZD compounds are selective PPARg
ligands, and PPARg is assumed to mediate most of their
pharmacological action (Lehmann et al, 1995). As expected,
troglitazone readily bound to ectopic PPARg in C50 cells as
demonstrated with the Gal4-PPARg-LBD and MH-100-TK-
LUC system (Nagy et al, 1998) (Fig 7a). As low as 0.2 mM
troglitazone effectively bound to PPARg ligand binding
domain and induced a 1.7-fold reporter expression,
although PPARa ligand (Wy-14643) did not. To test whether
PPARg is involved in the anti-proliferative effect of troglita-
zone in keratinocytes, we examined whether a functional
PPARg exists in keratinocytes. To do so, C50 cells were
transiently transfected with a PPRE reporter construct. As
shown in Fig 7b, troglitazone could not induce PPRE activity
in C50 cells. Rather, it inhibited it. It is important to note
that troglitazone also inhibited CMV-driven b-galactosi-
dase expression, an internal control used for transfection
(Fig 7b, inset). This is probably due to the inhibitory effect
of troglitazone on total protein synthesis. When a PPARg
expression vector was co-transfected with the PPRE
reporter construct, however, 1.8-fold induction of PPRE
activity was observed (Fig 7b). Although the induction was
modest, it was highly repeatable. The inhibitory effect of
troglitazone on PPRE basal activity in the absence of
exogenous PPARg may account for the modest induc-
tion. The modest induction of PPRE activity by troglitazone
Figure 4
Suppression of cyclin D1 mRNA levels by troglitazone (Trog). (a)
C50 cells were stimulated with fresh keratinocyte growth medium
(KGM-2) medium and treated with 5 mM Trog (Trog) for indicated
periods of time. Cyclin D1 mRNA levels were determined by Northern
blot analysis. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as a loading control. (b) Primary keratinocytes in six-well
plates were transiently transfected in triplicate with a luciferase reporter
gene under the control of a cyclin D1 promoter and treated with vehicle
or Trog (Trog 1–5 mM) for 24 h. Luciferase activity was measured and
normalized to an internal control (b-galactosidase). Data are presented
as mean  SD. po0.01 versus vehicle control. A set of representative
data from at least three independent experiments is presented. Figure5
Enhanced cyclin D1 protein degradation by troglitazone (Trog). C50
cells were pre-treated with specific proteasome inhibitor 200 mM Alln (a)
10 or 20 mM MG-132 (b) for 15 min. Cells were then treated with 5 mM
Trog (Trog) for an additional 6 h. Thirty mg protein from whole-cell
extracts was used for western blot analysis for cyclin D1 expression. b-
actin (actin) was used as a loading control. Densitometric quantitation
of the protein bands relative to actin expression is shown with the
vehicle only samples set as 1.0. (c) C50 cells were treated with vehicle
(lane 2), or 5 mM Trog (lane 3) for 6 h. 300 mg of whole-cell extract was
immunoprecipitated with a cyclin D1 antibody and immunoblotted with
an anti-ubiquitin antibody. The blot was then reprobed for cyclin D1 as
an immunoprecipitation control. Lane 1 was an immunoprecipitation
negative control (beads only). Lower panel: 1/10 of immunoprecipita-
tion inputs were immunoblotted with anti-b-actin (actin) as a loading
control. A set of representative data from at least two independent
experiments is presented.
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may also reflect the limited availability of other factors for
PPARg function in these cells such as retinoid X receptor
or PPARg co-activators. Similar results were obtained in
primary keratinocytes (data not shown). The above findings
prompted us to examine the expression of PPARg in
keratinocytes. Northern blot analysis with a mouse PPARg
cDNA probe showed that PPARg mRNA was not detectable
in C50 cells or in primary keratinocytes, and a strong band
at 2.1 kb (PPARg) was detected in the control RNA of mouse
fat tissue (Fig 7c). Western blot analysis repeatedly showed
that PPARg protein levels in these cells were below the limit
of detection, whereas PPARg protein was readily detectable
in differentiated preadipocytes even when 3-fold less
protein was loaded (Fig 7d). The two bands in the pre-
adipocyte sample were PPARg1 and PPARg2, respectively,
as verified by using PPARg1 or PPARg2-transfected 293 cell
lysates (data not shown). Taken together, these data
suggest that PPARg is not present at functional levels in cul-
tured keratinocytes. Thus, the inhibitory effect of troglita-
zone on cell proliferation or cyclin D1 expression is likely to
be PPARg-independent.
Figure 6
Inhibition of protein synthesis by troglitazone (Trog). C50 cells in
triplicate were treated with vehicle () or 5 mM Trog (þ ) for 5 h and
pulsed with [35S]methionine for an additional 1 h. (a) [35S]Methionine
incorporated by cells was measured. po0.05, versus vehicle control.
(b) [35S]methionine-labeled cyclin D1 was immunoprecipitated as
described in the Materials and Methods. The bands were quantitated
by densitometry and data are presented as % of control with vehicle
control set to 100%.
Figure 7
Absence of peroxisome proliferator-activated receptor c (PPARc)
function in keratinocytes. (a) C50 cells were transiently transfected in
triplicate with Gal4-PAPRg-LBD and MH-100-TK-LUC and treated with
troglitazone (Trog) (0.2–5 mM), or 10 mM Wy-14643 for 24 h. (b) C50 cells
were transiently transfected in triplicate with a (PPAR response element
(PPRE))3-TK-LUC construct along with an empty pcDNA3 vector () or
pcDNA3-PPARg (PPARg). Cells were treated with 5 mM Trog (Trog) for
24 h. Luciferase activity was measured and normalized to an internal
control (b-galactosidase). Inset of (b) shows the inhibition of 5 mM
Trog on expression of b-galactosidase, which is the combination
of five independent experiments. Data are presented as mean  SD.
po0.05 versus vehicle control. (c) Northern blot analysis was per-
formed to determine PPARg mRNA expression in primary keratinocytes
(PK) and in C50 cells. Total RNA from mouse fat tissue was used
as a positive control. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was measured as a loading control. (d) Western blot analysis
with 30 mg protein was performed for PPARg expression in PK and in
C50 cells. Ten micrograms protein from differentiated preadipocyte cell
lysate (Upstate, Waltham, Massachusetts) was included as a positive
control for PPARg expression. A set of representative data from at least
three independent experiments is presented.
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Consistent with the above conclusion, pre-treatment of
C50 cells with 1 mM GW9662, a potent PPARg antagonist,
failed to prevent the inhibitory effect of troglitazone on cell
proliferation (Fig 8a). On the other hand, GW9662 at the
same concentration effectively inhibited PPRE activity in
these cells in the presence of both troglitazone and
exogenous PPARg (cf. lane 2 vs 4 in Fig 8c), indicating that
GW9962 was working appropriately as a PPARg antagonist
at this concentration. To avoid the issue of possible non-
specificity of PPARg antagonists, a dnPPARg was intro-
duced into C50 cells by an adenovirus expression system.
A 100% infection was achieved as monitored by green
fluorescent protein (GFP) expression. The dnPPARg did not
alter the inhibitory effect of troglitazone on cell proliferation
or cyclin D1 expression (Fig 8b), although it did inhibit
PPARg-mediated induction of PPRE activity by troglitazone
(cf. lane 6 vs 8 in Fig 8d).
Discussion
A number of studies have demonstrated that activation of
PPARg inhibits cell growth and induces cell cycle arrest
(reviewed in Fajas et al, 2001). In their pioneer study, Altiok
et al (1997) showed that the TZD drug pioglitazone induced
growth arrest and adipose differentiation of PPARg-deficient
NIH-3T3 cells only when exogenous PPARg was introduced.
They found that activation of PPARg downregulated protein
Figure 8
Effects of GW9662 and a dn-PPARg (peroxisome proliferator-activated receptor c) on troglitazone (Trog) action in C50 cells. (a) C50 cells in
triplicate were pre-treated with 1 mM GW9662 for 15 min, or (b) were pre-infected with an adenovirus expressing a dominant negative PPARg (Ad-
dnPPARg) or a control adenovirus () for 12 h. Cells were then treated with vehicle () or 5 mM Trog (Trog) for an additional 24 h. Cells were pulsed
with 1 mCi per mL of [3H]thymidine for 2 h before harvest. The [3H]thymidine ([3H]TdR) incorporated by cells was measured and normalized to protein
concentration. (b) Inset: Cells were examined for cyclin D1 (upper band) and PPARg (middle band) expression by western blot analysis. b-actin
(lower band) was used as a loading control. (c) and (d) C50 cells were transiently transfected in triplicate with (PPAR response element (PPRE))3-TK-
LUC construct along with a pcDNA3-PPARg expression vector (PPARg) or a pcDNA empty vector (). Sixteen hours later, cells were treated with 1
mM GW9662 for 15 min (c) or infected with an adenovirus expressing a dominant negative PPARg (Ad-dnPPARg) or a control adenovirus () for 12 h
(d). Cells were treated with vehicle () or 5 mM Trog (Trogþ ) for an additional 24 h. Luciferase activity was measured and normalized to an internal
control (b-galactosidase). Data are presented as mean  SD. po0.01 versus lane 1 in (a)–(c); po0.01 versus lane 5 in (d). p40.05 versus lane 2
in (a) and (b); po0.01 versus lane 2 in (c) and lane 6 in (d). A set of representative data from at least two independent experiments is presented.
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phosphatase PP2A and thus inhibited the transcriptional
activity of the E2F/DP complex due to an increase in the
phosphorylation of these proteins. The inhibitory effect of
PPARg ligands on cell growth can also be the result of
transcriptional upregulation of PTEN, a tumor suppressor
gene, by PPARg (Patel et al, 2001). PPARg induces PTEN
transcription by binding to two PPAR response elements in
the sequence upstream of the PTEN gene (Patel et al, 2001).
On the other hand, PPARg is not always required for some
PPARg ligands to induce cell growth arrest. For example,
TZD inhibit cell growth equally efficiently in PPARgþ /þ and
PPARg/ mouse embryonic stem cells (Palakurthi et al,
2001). These studies clearly suggest that TZD may inhibit
cell growth through PPARg-dependent and/or PPARg-
independent mechanisms in a given cell context.
Our results suggest that troglitazone affects proliferation
of keratinocytes through a PPARg-independent pathway.
The fundamental evidence for this is that troglitazone could
not elicit PPRE activity in the cells unless exogenous PPARg
was introduced. In addition, neither PPARg antagonists nor
ectopic expression of a dominant negative PPARg counter-
acted the inhibitory effect of troglitazone on cell prolifera-
tion. Although we do not exclude the possibility that PPARg
function is turned off through phosphorylation of PPARg by
MAP kinase (Hu et al, 1996), we believe that PPARg is
not present at functional levels in C50 cells or primary
keratinocytes. We showed that PPARg levels in these cells
are below the limit of detection by Northern or Western blot
analysis. This is, however, not completely in agreement with
the observation that normal mouse skin expresses a low
level of PPARg, especially in the epidermis of newborn pups
(Thuillier et al, 2000; Michalik et al, 2001). Interestingly,
PPARg expression in human skin was found to be confined
to the suprabasal layers and its expression in cultured
human keratinocytes was also barely detectable (Wester-
gaard et al, 2001). These findings suggest that PPARg
expression in human skin keratinocytes is associated with
keratinocyte differentiation (Westergaard et al, 2001). The
lack of functional levels of PPARg in cultured mouse skin
keratinocytes may be because the cultured keratinocytes
are undifferentiated.
The pathway by which PPARg ligands induce cell cycle
arrest is under intense study. Cdk inhibitor p21 is known
to be involved in PPARg-induced adipose differentiation.
Interestingly, p21 expression is also upregulated by trogli-
tazone in several tumor cells (Koga et al, 2001; Kim et al,
2002). p21 causes G1 arrest through inhibiting phosphor-
ylation of Rb by cdks and inhibiting G1-S transition.
Consistent with this, Rb/ mouse embryo fibroblasts are
resistant to PPARg ligand-induced G1 phase arrest (Fajas
et al, 2003). Our data show that p21 expression is not
altered for up to 24 h by troglitazone in our cells. We
demonstrated, however, that troglitazone strongly sup-
pressed mitogen-induced cyclin D1 expression in keratino-
cytes. Inhibition of D-type cyclins can also cause G1 arrest
because phosphorylation of Rb by cdk4/6 at the G1–S
transition depends on the availability of D-type cyclins. D-
type cyclins play a critical role in growth factor signaling and
cell cycling and are targets for genetic and epigenetic
alterations that underlie the development of many human
neoplasias. For example, cyclin D1 is commonly over-
expressed in many tumor types, and constitutive over-
expression of cyclin D1 in mouse mammary glands leads to
development of carcinomas (Wang et al, 1994). In addition,
overexpression of cyclin D1 in keratinocytes has been
shown to cause increased proliferation and to partially
override anti-tumorigenic signals (Martinez et al, 2000).
Thus, inhibition of cyclin D1 expression appears to be a
possible mechanism underlying the anti-proliferative effect
of troglitazone in keratinocytes. Inhibition of expression of
cdk2/4 may also contribute to the anti-proliferative effect of
TZD. Clearly the mechanisms remain unclear and require
further study.
It has been reported that the PPARg ligand 15-PGJ2
inhibited cyclin D1 transcription by activating PPARg in
MCF-7 cells (Wang et al, 2001). Ligand-bound PPARg
competes for the limited amount of co-activator p300 that
is required for c-fos-mediated cyclin D1 transcription
(Wang et al, 2001). We demonstrated a similar inhibition of
cyclin D1 transcription by troglitazone in keratinocytes.
The mechanisms by which troglitazone inhibited cyclin D1
transcription in keratinocytes is not clear, but it is likely to be
PPARg-independent for the reasons described above. We
demonstrated that alteration in cyclin D1 protein degrada-
tion was also involved in the regulation of cyclin D1 protein
expression by troglitazone in keratinocytes. This is indicated
by the ability of proteasome inhibitors to inhibit the effect
of troglitazone on cyclin D1 expression. We verified this
observation by showing that troglitazone increased the
ubiquitination of cyclin D1 protein, a process that is required
for cyclin D1 degradation through the proteasome pathway.
Interestingly, the PPARg ligands, ciglitazone, and 15-PGJ2,
are also shown to enhance cyclin D1 protein degradation in
MCF-7 cells (Qin et al, 2003). Further study is needed to
clarify the underlying mechanism.
Cellular proliferation is stimulated by extracellular mito-
gens through receptor-mediated signaling pathways. D-
type cyclins function as critical sensors of these signals.
Their expression is triggered and maintained by mitogenic
stimulation, regardless of the position of the cell in the cycle,
and growth factor withdrawal leads to rapid cyclin D protein
destruction and G1-phase arrest (Sherr, 1995). Our results
show that troglitazone rapidly and effectively inhibited
mitogen-induced cyclin D1 expression and caused a G1
phase arrest in keratinocytes. It caused no inhibition of
basal expression of cyclin D1, thus it appears likely that
troglitazone may somehow inhibit mitogen signaling in
these cells. Indeed, PPARg ligands have been found to
affect the extracellular signal-regulated kinase (Erk) path-
way. In human macrophages and endothelial cells the
PPARg ligand 15-PGJ2 was found to block activation of
Erk1/2 by lipopolysaccharides and tumor necrosis factor a
independent of PPARg (Eligini et al, 2002). In most other
cells, however, PPARg ligands activate the Erk pathway
(Huang et al, 2002; Kim et al, 2002; Lennon et al, 2002). How
PPARg ligands interact with the Erk pathway is not clear,
but involvement of reactive oxygen species has been
suggested (Lennon et al, 2002). Nevertheless, a critical
question that remains unanswered is whether altered
activation of the Erk pathway is associated with the growth
arrest action of PPARg ligands in those cells. In addition to
their effect on the Erk signaling, PPARg ligands are also able
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to interfere with growth factor receptor activation (Pignatelli
et al, 2001; Gardner et al, 2003). In one study, PPARg ligand
15-PGJ2 was found to inhibit ligand-induced ErbB-2 and
ErbB-3 tyrosine phosphorylation and to abolish ligand-
induced cell proliferation in MCF-7 cells (Pignatelli et al,
2001). Although we do not know exactly how troglitazone
inhibits mitogen-induced cyclin D1 expression and cell
proliferation in mouse skin keratinocytes, it is likely that
growth factor signaling is impaired by troglitazone in these
cells.
Whether the inhibition of total protein synthesis is a
general toxic effect of troglitazone is uncertain. First, the
concentration of troglitazone (5 mM) used is low and there
were no signs of cell stress and cell death when cells were
treated with troglitazone at this concentration. Secondly,
it has been shown that troglitazone inhibited translation
initiation in mouse embryonic stem cells independently of
PPARg through partial depletion of intracellular calcium
stores and the resulting activation of protein kinase R
(Palakurthi et al, 2001). Furthermore, the inhibited protein
synthesis may contribute only partially to troglitazone’s
effects on cell proliferation and cell cycle arrest. The
stronger inhibition by troglitazone on cyclin D1 incorpora-
tion of [35S]methionine than on total protein synthesis could
be the result of inhibited cyclin D1 transcription as well as
the result of enhanced cyclin D1 protein degradation.
Hence, it is likely that the observed effect of troglitazone
on cell proliferation or cell cycle arrest in C50 is not entirely
due to toxicity.
In the mouse skin two-stage carcinogenesis model,
tumor promotion is a rate-limiting step for tumor formation.
It is proposed that the increased cellular proliferation during
the promotion stage leads to selective clonal expansion of
initiated cells, which makes it possible for an initiated cell
to subsequently accumulate enough genetic mutations
required for cancer development. Our data clearly show
that both troglitazone and ciglitazone inhibit cellular
proliferation of normal primary keratinocytes and initiated
keratinocytes (C50 cells) in vitro. Given the important role of
keratinocyte proliferation in mouse skin carcinogenesis, our
data suggest that TZD may have utility in tumor prevention
in mouse skin.
Materials and Methods
Cell culture Primary keratinocytes were prepared as described
previously (Thuillier et al, 2000). Briefly, 1–2-d-old SSIN newborns
were euthanized. The epidermal keratinocytes were harvested by
trypsinization, pooled and plated in enriched Waymouth’s medium
containing 1.2 mM calcium and 10% fetal bovine serum. The cells
were allowed to attach at 371C in 5% CO2 for 2.5 h, and medium
was then replaced with serum-free KGM-2 (Biowhittaker, Walkers-
ville, Maryland) containing 0.03 mM calcium. C50 cells, a non-
tumorigenic keratinocyte cell line (a gift from Dr A.J.P. Klein-Szanto,
Fox Chase Cancer Center, Philadelphia, Pennsylvania) derived
from spontaneously immortalized normal mouse skin keratinocytes
(Ruggeri et al, 1991), were maintained and plated at 371C in 5%
CO2 in Eagle’s Minimal Essential Medium (EMEM) supplemented
with 1% fetal bovine serum and a variety of growth factors as
described (Dotto et al, 1988). The EMEM medium was replaced
with KGM-2 medium containing 0.03 mM of calcium 16 h after
plating. Both primary keratinocytes and C50 cells were plated at a
density such that they would become about 80% confluent by the
third day of growing in KGM-2 without changing medium (except
where otherwise described). The cells were then stimulated with
pre-warmed, fresh KGM-2 medium containing vehicle or appro-
priate treatment. All animal experiments were approved by the
institutional animal use committee at the University of Texas, MD
Anderson Cancer Center and were performed in accordance with
the principles and procedures outlined in the NIH guidelines for the
care and use of experimental animal.
Chemicals PPARg ligands, troglitazone, and ciglitazone, were
gifts from Parke-Davis Pharmaceutical Research Division of Warner-
Lambert Company (Ann Arbor, Michigan). PPARa ligand 4-chloro-
6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (Wy-14643) was pur-
chased from Chemsyn Science Laboratories (Lenexa, Kansas).
Proteasome inhibitors Alln and MG-132 were purchased from
CalBioChem (La Jolla, California). PPARg antagonist GW-9662 was
purchased from Cayman Chemical (Ann Arbor, Michigan). All
chemicals were dissolved in dimethyl sulfoxide.
[3H]Thymidine incorporation assay Primary keratinocytes or
C50 cells grown to 80% confluence in six-well plates were treated
in triplicate with vehicle or PPARg ligands for 3–24 h. Two hours
prior to harvest, cells were pulsed with 1 mCi per mL of [3H-
methyl]thymidine ([3H]thymidine) (CalBioChem, UK). The medium
was removed and cells were rinsed twice with ice-cold phosphate-
buffered saline. Cells were then incubated on ice with ice-cold
10% (w/v) trichloroacetic acid for 10 min once and 5 min twice to
fix cells and precipitate DNA. The cells were lysed with 1 mL per
well of lysis buffer containing 0.3 N NaOH, 1% sodium dodecyl
sulfate (SDS) for 15 min at room temperature. Cell lysates were
transferred to scintillation vials containing 5 mL scintillation liquid
and mixed well. [3H]thymidine radioactivity was measured and the
values were normalized to protein concentration.
Flow cytometry C50 cells at 80% confluence in 100 mm dishes
were treated with PPARg ligands for 24 h and harvested by
trypsinization. Single cell suspensions were obtained by filtering
the cells through a 70 mm mesh once. Cells were fixed on ice in ice-
cold 70% ethanol for 1 h and stained with 0.5 mL propidium iodide
phosphate-buffered saline solution (40 mg per mL). The stained
cells were diluted with propidium iodide solution to about 5  105
cells per mL and analyzed on a Coulter EPICS Elite flow cytometer
(Coulter, Clarkson, Michigan) using a 610 nm bypass filter and
aggregate discrimination. Cell cycle analysis was carried out using
Multicycle DNA cell cycle analysis software from Phoenix Flow
systems (San Diego, California).
Western blot analysis Western blot analysis was performed as
previously described (Thuillier et al, 2000). Thirty micrograms of
whole cell lysate of each sample was heated at 951C for 10 min,
denatured and fractionated by 10% SDS-polyacrylamide gel
electrophoresis and transferred to polyvinylidene difluoride mem-
branes. The blots were blocked for 1 h in Tris-buffered saline
containing 5% non-fat milk and 0.1% Tween 20. They were
immunostained at room temperature for an additional 1 h with
antibodies against cyclin D1 (C-20), cyclin A, cyclin B1, cyclin E,
cdk2, cdk4, p21, or PPARg (E-8) (Santa Cruz Biotechnology, Santa
Cruz, California). The blots were washed extensively with Tris-
buffered saline with 0.1% Tween-20. Bound primary antibody was
detected with horseradish peroxidase-conjugated second anti-
body and chemiluminescent substrate (Perkin-Elmer Life Science,
Boston, Massachusetts). b-actin was used as a loading control.
[35S]methionine incorporation assay C50 cells in triplicate were
treated with vehicle or 5 mM troglitazone for 5 h and pulsed with
200 mCi per mL [35S]methionine (ICN, Costa Mesa, California)
in methionine-free EMEM medium for an additional 1 h. Cells
were washed twice with ice-cold phosphate-buffered saline and
harvested in radioimmunoprotein assay buffer. Whole-cell lysates
were obtained by centrifugation for 15 min at 13,000 g Protein
concentration was determined with the BCA kit (Bio-Rad,
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Richmond, California). Three hundred micrograms of total protein
was each used for measurement of [35S]methionine radioactivity
and for cyclin D1 immunoprecipitation. Cyclin D1 protein im-
munoprecipitation was performed as described in the follow-
ing section ‘‘detection of cyclin D1 protein degradation’’ and
fractionated by 10% SDS-polyacrylamide gel electrophoresis. The
gel was dried and exposed to an X-ray film.
Northern blot analysis Total RNA was extracted with Tri-Reagent
(MRC, Cincinnati, Ohio) following the manufacturer’s protocol. Ten
micrograms of total RNA of each sample was denatured and
separated on 1% agarose/6% formaldehyde gel, and then trans-
ferred to nylon membranes. A [32P]dCTP-labeled cDNA probe of
cyclin D1 or PPARg was hybridized to the blots at 651C for 2 h. The
blots were then washed twice each for 15 min in 0.1% SDS/
2  NaCl/sodium citrate solution (where 1x is 0.15 M NaCl/15 mM
sodium citrate) at room temperature and once for 30 min with 0.1%
SDS/0.1  NaCl/sodium citrate solution at 601C and exposed to X-
ray film at 801C. The blots were stripped and reprobed with
glyceraldehyde-3-phosphate dehydrogenase cDNA as a loading
control.
Detection of cyclin D1 protein degradation To determine if
troglitazone promotes cyclin D1 protein degradation through the
proteasome pathway, C50 cells at about 80% confluence were
pre-treated with proteasome inhibitor Alln or MG-132 for 15 min
before application of troglitazone. Whole cell protein was extracted
in radioimmunoprotein assay buffer. Cyclin D1 levels were
measured by western blot analysis. To determine ubiquitination
of cyclin D1 protein, C50 cells were treated with vehicle, or 5 mM
troglitazone for 6 h and whole cell protein was extracted. Three
hundred mg of total protein was incubated with 10 mg cyclin D1
antibody (Santa Cruz Biotechnology) at 41C overnight. Protein A
agarose beads were then directly added to each sample and
incubated at 41C for an additional 1 h. The beads were washed
four times with radioimmunoprotein assay buffer by short spin and
immunoprecipitates were eluted from the beads with 30 mL of
1  SDS sample buffer. The eluted proteins were heated at 951C
for 10 min, processed for Western blot analysis and immunos-
tained with an anti-ubiquitin antibody (P4D1, Santa Cruz Biotech-
nology). The blot was stripped and reprobed with cyclin D1
antibody as an immunoprecipitation control. As a loading control,
thirty mg of total protein of each sample was loaded along with the
immunoprecipitation sample and transferred to the same blot and
probed with anti-b-actin antibody (Santa Cruz Biotechnology).
Transient transfection Primary keratinocytes (1  106 per well) or
C50 cells (4  105 per well) were plated in six-well plates and
grown to about 60% confluence the next day. Following replace-
ment of medium with fresh KGM-2, cells were transfected with
plasmid(s) as indicated below for 16 h using Fugene 6 (Roche
Diagnostics, Indianapolis, Indiana) with a DNA: Fugene 6 ratio of 1
mg:3 mL. To test the effect of troglitazone on cyclin D1 promoter
activity, each well was transfected with 1 mg of a luciferase reporter
construct driven by a 1745 bp cyclin D1 promoter (a kind gift from
Dr Chris Albanese, The Albert Einstein Cancer Center, New York,
New York). To test for the ability of troglitazone to bind to PPARg
in C50 cells, cells were co-transfected with 1 mg per well Gal4-
PPARg-LBD and 1 mg per well MH-100-TK-LUC (a generous gift
from Dr R.M. Evans, The Salk Institute, San Diego, California).
Gal4-PPARg-LBD is a chimeric receptor in which the ligand-
binding domain (LBD) of mouse PPARg is fused to the DNA-binding
domain of the yeast transcription factor Gal4. The chimeric
receptor is able to bind to the Gal4 DNA binding motif but
activates transcription only in response to ligands bound to the
LBD of PPARg (Nagy et al, 1998). To test for the ability of
troglitazone to activate PPRE activity, cells were co-transfected
with 1 mg per well of a PPRE luciferase reporter construct (PPRE)3-
TK-LUC (generously provided by Dr R.M. Evans), along with 1 mg
per well of a pcDNA3-PPARg expressing vector (a kind gift from Dr
V.K. Chatterjee, University of Cambridge, UK) or 1 mg per well of
the empty pcDNA3 vector (Invitrogen, Carlsbad, California). As
an internal control, 0.125 mg per well of pCMV-b-galactosidase
plasmid was always co-transfected. After 16 h, cells were given
fresh pre-warmed KGM-2 medium and treated with vehicle or
troglitazone or other PPAR ligands for an additional 24 h. Protein
was extracted in luciferase lysis buffer (Tropix, Bedford, Massa-
chusetts). Luciferase activity was measured by a luminometer
(Tropix) and normalized to the b-galactosidase activity.
Generation and use of adenovirus expressing a dominant
negative PPARc The flag epitope-tagged human dominant nega-
tive PPARg (dnPPARg) cDNA was obtained by cutting the pcDNA-
dnPPARg (Gurnell et al, 2000) (a kind gift from Dr V.K. Chatterjee,
University of Cambridge, Cambridge, UK) with KpnI/XbaI. The
cDNA was put into a pAd-track vector at the KpnI/XbaI sites and
then cloned into pAdEasy-1 adenovirus vector by homologous
recombination according to the manual supplied with the AdEasy
XL adenoviral vector system (Stratagene, La Jolla, California). The
empty pAd-track vector was also cloned into pAdEasy-1 as a
control. The adenovirus pAd-track-dnPPARg and pAd-track, which
express the dnPPARg plus GFP and control GFP alone, respec-
tively, were produced and amplified in Ad-293 cells and purified by
CsCl gradient centrifugation. In the experiments where adenovirus
vectors were used, cells were pre-incubated with pAd-track-
dnPPARg and pAd-track-GFP at a multiplicity of infection of 1:20
for 12 h and troglitazone was directly added into the medium.
Statistics Data obtained from the [3H]thymidine incorporation
assays, [35S]methionine incorporation assay and from the transient
transfection assays were analyzed with one-way ANOVA to
compare means between the vehicle control and treatment groups
using SPSS 10 (SPSS Mac V.10, SPSS, Chicago, Illinois).
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